UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 126

Sortiert nach

New clinical trial designs in the era of precision medicine

Molecular oncology, 2019-03, Vol.13 (3), p.549-557

2019

Link zum Volltext

Verfügbarkeit prüfen

Toxicity as a Biomarker of Efficacy of Molecular Targeted Therapies: Focus on EGFR and VEGF Inhibiting Anticancer Drugs

The oncologist (Dayton, Ohio), 2011-12, Vol.16 (12), p.1729-1740

2011

Link zum Volltext

Verfügbarkeit prüfen

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

Nature Medicine, 2019-05, Vol.25 (5), p.751-758

2019

Link zum Volltext

Verfügbarkeit prüfen

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

British journal of cancer, 2020-12, Vol.123 (12), p.1730-1736

2020

Link zum Volltext

Verfügbarkeit prüfen

LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8 + T cell tumor-infiltration impairing anti-PD1 therapy

Nature communications, 2019-06, Vol.10 (1), p.2416-2416, Article 2416

2019

Link zum Volltext

Verfügbarkeit prüfen

Overview of Oral Potentially Malignant Disorders: From Risk Factors to Specific Therapies

Cancers, 2021-07, Vol.13 (15), p.3696

2021

Link zum Volltext

Verfügbarkeit prüfen

BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas

Nature communications, 2023-03, Vol.14 (1), p.1359-1359, Article 1359

2023

Link zum Volltext

Verfügbarkeit prüfen

First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma

Clinical cancer research, 2015-02, Vol.21 (3), p.553-560

2015

Link zum Volltext

Verfügbarkeit prüfen

Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria

Clinical cancer research, 2020-04, Vol.26 (8), p.1846-1855

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

Investigational new drugs, 2014-08, Vol.32 (4), p.670-681

2014

Link zum Volltext

Verfügbarkeit prüfen

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers

Nature communications, 2023-02, Vol.14 (1), p.630-630, Article 630

2023

Link zum Volltext

Verfügbarkeit prüfen

Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment

BMC medicine, 2012-12, Vol.10 (1), p.161-161, Article 161

2012

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study

Investigational new drugs, 2021-10, Vol.39 (5), p.1275-1283

2021

Link zum Volltext

Verfügbarkeit prüfen

Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours

European journal of cancer (1990), 2023-10, Vol.192, p.113259-113259, Article 113259

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Clinical cancer research, 2014, Vol.20 (1), p.233-245

2014

Link zum Volltext

Verfügbarkeit prüfen

Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial

Clinical cancer research, 2015-01, Vol.21 (1), p.49-59

2015

Link zum Volltext

Verfügbarkeit prüfen

A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy

International journal of molecular sciences, 2022-12, Vol.24 (1), p.118

2022

Link zum Volltext

Verfügbarkeit prüfen

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study

Clinical cancer research, 2022-07, Vol.28 (13), p.2762-2770

2022

Link zum Volltext

Verfügbarkeit prüfen

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

Clinical cancer research, 2015-04, Vol.21 (8), p.1888-1895

2015

Link zum Volltext

Verfügbarkeit prüfen

Response to “Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias”

Cancer treatment reviews, 2022-12, Vol.111, p.102465, Article 102465

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 126

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(123)
Mit Volltextzugriff
(122)

Publikationsform

Artikel
(125)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(60)
Life Sciences & Biomedicine
(57)
Oncology
(48)
Humans
(43)
Female
(25)
Middle Aged
(23)
Male
(21)
Aged
(20)
Adult
(19)
Patients
(19)
Tumors
(17)
Medicine
(16)
Neoplasms - Drug Therapy
(15)
Cancer
(12)
Immunotherapy
(12)
Medicine & Public Health
(12)
Antineoplastic Agents - Adverse Effects
(9)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)
Biomarkers
(9)
Clinical Trials
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

New clinical trial designs in the era of precision medicine

Toxicity as a Biomarker of Efficacy of Molecular Targeted Therapies: Focus on EGFR and VEGF Inhibiting Anticancer Drugs

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8 + T cell tumor-infiltration impairing anti-PD1 therapy

Overview of Oral Potentially Malignant Disorders: From Risk Factors to Specific Therapies

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy

BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas

First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial

Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria

A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors

Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment

Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study

Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours

PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial

A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

Response to “Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias”

Suchergebnisse filtern